Maria Barilli, Giulia Elena Mandoli, Nicolò Sisti, Aleksander Dokollari, Nicolò Ghionzoli, Hatem Soliman-Aboumarie, Flavio D'Ascenzi, Marta Focardi, Luna Cavigli, Maria Concetta Pastore, Matteo Cameli
Pulmonary vein isolation (PVI) with catheter ablation (CA) represents an effective therapy for atrial fibrillation (AF). Unfortunately, it is still not exempt from severe complications. The balance of risks and benefits should be assessed, and a patient-tailored approach is desirable. So far, several clinical and cardiac imaging parameters have been evaluated to investigate pre- and post-procedural features that could help clinicians in the selection of patients at high risk of a poor outcome after CA. This clinical and systematic review analyses the potential role of new LA parameters, such as LA reservoir strain, to predict AF recurrence after CA therapy. Notably, LA reservoir strain gains substantial clinical importance in patients with paroxysmal AF and when a low CHADS2-VASc score is retrieved. LA reservoir strain provides data concerning the risk of AF recurrence after PVI and, thus, in the management of long-term medical therapy in this patient's group.
导管消融术(CA)肺静脉隔离术(PVI)是治疗心房颤动(AF)的有效疗法。遗憾的是,它仍然无法避免严重的并发症。应评估风险与收益之间的平衡,最好能采取适合患者的方法。迄今为止,已对一些临床和心脏成像参数进行了评估,以研究手术前后的特征,帮助临床医生选择房颤术后预后不良的高风险患者。本临床和系统性综述分析了新的 LA 参数(如 LA 储库应变)在预测 CA 治疗后房颤复发方面的潜在作用。值得注意的是,对于阵发性房颤患者和 CHADS2-VASc 评分较低的患者,LA 储腔应变具有重要的临床意义。LA 储库应变提供了有关 PVI 后房颤复发风险的数据,因此对这类患者的长期药物治疗管理具有重要意义。
{"title":"Potential Role of Left Atrial Strain to Predict Atrial Fibrillation Recurrence after Catheter Ablation Therapy: A Clinical and Systematic Review.","authors":"Maria Barilli, Giulia Elena Mandoli, Nicolò Sisti, Aleksander Dokollari, Nicolò Ghionzoli, Hatem Soliman-Aboumarie, Flavio D'Ascenzi, Marta Focardi, Luna Cavigli, Maria Concetta Pastore, Matteo Cameli","doi":"10.3390/jcdd11070203","DOIUrl":"10.3390/jcdd11070203","url":null,"abstract":"<p><p>Pulmonary vein isolation (PVI) with catheter ablation (CA) represents an effective therapy for atrial fibrillation (AF). Unfortunately, it is still not exempt from severe complications. The balance of risks and benefits should be assessed, and a patient-tailored approach is desirable. So far, several clinical and cardiac imaging parameters have been evaluated to investigate pre- and post-procedural features that could help clinicians in the selection of patients at high risk of a poor outcome after CA. This clinical and systematic review analyses the potential role of new LA parameters, such as LA reservoir strain, to predict AF recurrence after CA therapy. Notably, LA reservoir strain gains substantial clinical importance in patients with paroxysmal AF and when a low CHADS2-VASc score is retrieved. LA reservoir strain provides data concerning the risk of AF recurrence after PVI and, thus, in the management of long-term medical therapy in this patient's group.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonino Maniaci, Salvatore Lavalle, Federica Maria Parisi, Marco Barbanti, Salvatore Cocuzza, Giannicola Iannella, Giuseppe Magliulo, Annalisa Pace, Mario Lentini, Edoardo Masiello, Luigi La Via
A prevalent condition linked to an elevated risk of cardiovascular disease is sleep apnea. This review examines the connections between cardiac risk, the sympathetic nervous system, and sleep apnea. The increased risk of hypertension, arrhythmias, myocardial infarction, and heart failure was highlighted in the pathophysiology of sleep apnea and its effect on sympathetic activation. It is also important to consider potential processes such as oxidative stress, inflammation, endothelial dysfunction, and autonomic imbalance that may relate sleep apnea-induced sympathetic activation to cardiac risk. With implications for creating innovative diagnostic and treatment approaches to lessen the cardiovascular effects of sleep apnea, the goal of this investigation is to improve the understanding of the intricate link between sympathetic activity, cardiac risk, and sleep apnea. This study aimed to clarify the complex relationship between cardiovascular health and sleep apnea by synthesizing the available research and highlighting the crucial role played by the sympathetic nervous system in moderating this relationship. Our thorough investigation may have important therapeutic ramifications that will direct the creation of focused therapies to enhance cardiovascular outcomes in sleep apnea sufferers.
{"title":"Impact of Obstructive Sleep Apnea and Sympathetic Nervous System on Cardiac Health: A Comprehensive Review.","authors":"Antonino Maniaci, Salvatore Lavalle, Federica Maria Parisi, Marco Barbanti, Salvatore Cocuzza, Giannicola Iannella, Giuseppe Magliulo, Annalisa Pace, Mario Lentini, Edoardo Masiello, Luigi La Via","doi":"10.3390/jcdd11070204","DOIUrl":"10.3390/jcdd11070204","url":null,"abstract":"<p><p>A prevalent condition linked to an elevated risk of cardiovascular disease is sleep apnea. This review examines the connections between cardiac risk, the sympathetic nervous system, and sleep apnea. The increased risk of hypertension, arrhythmias, myocardial infarction, and heart failure was highlighted in the pathophysiology of sleep apnea and its effect on sympathetic activation. It is also important to consider potential processes such as oxidative stress, inflammation, endothelial dysfunction, and autonomic imbalance that may relate sleep apnea-induced sympathetic activation to cardiac risk. With implications for creating innovative diagnostic and treatment approaches to lessen the cardiovascular effects of sleep apnea, the goal of this investigation is to improve the understanding of the intricate link between sympathetic activity, cardiac risk, and sleep apnea. This study aimed to clarify the complex relationship between cardiovascular health and sleep apnea by synthesizing the available research and highlighting the crucial role played by the sympathetic nervous system in moderating this relationship. Our thorough investigation may have important therapeutic ramifications that will direct the creation of focused therapies to enhance cardiovascular outcomes in sleep apnea sufferers.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juan Esteban Gómez-Mesa, Manuela Escalante, Juan Andrés Muñoz-Ordoñez, Valeria Azcárate-Rodriguez, Juan David Peláez-Martínez, Andrea Alejandra Arteaga-Tobar, Hoover León-Giraldo, Andrea Valencia-Orozco, Eduardo Roque Perna, Alexander Romero, Iván Mendoza, Fernando Wyss, José Luis Barisani, Mario Speranza, Walter Alarco, Cesar Herrera, Julián Lugo-Peña, Liliana Patricia Cárdenas-Aldaz, Victor Rossel, Daniel Sierra
Background: The COVID-19 pandemic has highlighted a correlation between cardiac complications and elevated cardiac biomarkers, which are linked to poorer clinical outcomes.
Objective: This study aims to determine the clinical impact of cardiac biomarkers in COVID-19 patients in Latin America.
Subjects and methods: The CARDIO COVID 19-20 Registry is a multicenter observational study across 44 hospitals in Latin America and the Caribbean. It included hospitalized COVID-19 patients (n = 476) who underwent troponin, natriuretic peptide, and D-dimer tests. Patients were grouped based on the number of positive biomarkers.
Results: Among the 476 patients tested, 139 had one positive biomarker (Group C), 190 had two (Group B), 118 had three (Group A), and 29 had none (Group D). A directly proportional relationship was observed between the number of positive biomarkers and the incidence of decompensated heart failure. Similarly, there was a proportional relationship between the number of positive biomarkers and increased mortality. In Group B, patients with elevated troponin and natriuretic peptide and those with elevated troponin and D-dimer had 1.4 and 1.5 times higher mortality, respectively, than those with elevated natriuretic peptide and D-dimer.
Conclusions: In Latin American COVID-19 patients, a higher number of positive cardiac biomarkers is associated with increased cardiovascular complications and mortality. These findings suggest that cardiac biomarkers should be utilized to guide acute-phase treatment strategies.
{"title":"Association of Abnormal Cardiac Biomarkers and Cardiovascular Complications, with Mortality in Patients with SARS-CoV-2 Infection in Latin America.","authors":"Juan Esteban Gómez-Mesa, Manuela Escalante, Juan Andrés Muñoz-Ordoñez, Valeria Azcárate-Rodriguez, Juan David Peláez-Martínez, Andrea Alejandra Arteaga-Tobar, Hoover León-Giraldo, Andrea Valencia-Orozco, Eduardo Roque Perna, Alexander Romero, Iván Mendoza, Fernando Wyss, José Luis Barisani, Mario Speranza, Walter Alarco, Cesar Herrera, Julián Lugo-Peña, Liliana Patricia Cárdenas-Aldaz, Victor Rossel, Daniel Sierra","doi":"10.3390/jcdd11070205","DOIUrl":"10.3390/jcdd11070205","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic has highlighted a correlation between cardiac complications and elevated cardiac biomarkers, which are linked to poorer clinical outcomes.</p><p><strong>Objective: </strong>This study aims to determine the clinical impact of cardiac biomarkers in COVID-19 patients in Latin America.</p><p><strong>Subjects and methods: </strong>The CARDIO COVID 19-20 Registry is a multicenter observational study across 44 hospitals in Latin America and the Caribbean. It included hospitalized COVID-19 patients (<i>n</i> = 476) who underwent troponin, natriuretic peptide, and D-dimer tests. Patients were grouped based on the number of positive biomarkers.</p><p><strong>Results: </strong>Among the 476 patients tested, 139 had one positive biomarker (Group C), 190 had two (Group B), 118 had three (Group A), and 29 had none (Group D). A directly proportional relationship was observed between the number of positive biomarkers and the incidence of decompensated heart failure. Similarly, there was a proportional relationship between the number of positive biomarkers and increased mortality. In Group B, patients with elevated troponin and natriuretic peptide and those with elevated troponin and D-dimer had 1.4 and 1.5 times higher mortality, respectively, than those with elevated natriuretic peptide and D-dimer.</p><p><strong>Conclusions: </strong>In Latin American COVID-19 patients, a higher number of positive cardiac biomarkers is associated with increased cardiovascular complications and mortality. These findings suggest that cardiac biomarkers should be utilized to guide acute-phase treatment strategies.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xinglin Yang, Jin Huang, Jinghong Zhang, Jian Li, Zhuang Tian
Background: Amyloid light-chain (AL) amyloidosis is a multisystem disorder, with cardiac amyloid infiltration being a prevalent manifestation. This study aimed to explore the prognostic value of galectin-3 (Gal-3), a soluble marker associated with fibrosis, inflammation, heart failure, and kidney injury, in patients with cardiac AL amyloidosis.
Methods: A total of 60 patients who were diagnosed with cardiac AL amyloidosis from January 2015 to May 2018 were enrolled. The prognostic value of Gal-3 was assessed. Receiver operating characteristic (ROC) curves were used to evaluate the predictive accuracy of Gal-3. A Gal-3 cut-off value was identified to predict survival rates.
Results: The ROC curves demonstrated a moderate predictive accuracy of Gal-3 for 0.5- and 5-year survival, with area under the curve (AUC) values of 0.722 and 0.788, respectively. A Gal-3 cut-off value of 15.154 ng/mL was found to predict survival. Kaplan-Meier survival analysis revealed a significant difference in mean overall survival between patients with Gal-3 levels below and above the established cut-off (69.2 months versus 42.1 months, respectively; p = 0.036). Multivariate analysis confirmed that Gal-3 > 15.154 ng/mL remained an independent predictor of survival (HR 2.451, 95% CI 1.017-5.910, p = 0.046).
Conclusions: This study suggests that Gal-3 holds independent prognostic value for survival in patients with cardiac AL amyloidosis. Gal-3 could potentially enhance the prognostic capabilities of the current soluble markers, thereby improving the management of cardiac AL amyloidosis. However, further validation in larger prospective studies is warranted.
{"title":"Prognostic Value of Serum Galectin-3 for Survival in Patients with Cardiac Light-Chain Amyloidosis.","authors":"Xinglin Yang, Jin Huang, Jinghong Zhang, Jian Li, Zhuang Tian","doi":"10.3390/jcdd11070202","DOIUrl":"10.3390/jcdd11070202","url":null,"abstract":"<p><strong>Background: </strong>Amyloid light-chain (AL) amyloidosis is a multisystem disorder, with cardiac amyloid infiltration being a prevalent manifestation. This study aimed to explore the prognostic value of galectin-3 (Gal-3), a soluble marker associated with fibrosis, inflammation, heart failure, and kidney injury, in patients with cardiac AL amyloidosis.</p><p><strong>Methods: </strong>A total of 60 patients who were diagnosed with cardiac AL amyloidosis from January 2015 to May 2018 were enrolled. The prognostic value of Gal-3 was assessed. Receiver operating characteristic (ROC) curves were used to evaluate the predictive accuracy of Gal-3. A Gal-3 cut-off value was identified to predict survival rates.</p><p><strong>Results: </strong>The ROC curves demonstrated a moderate predictive accuracy of Gal-3 for 0.5- and 5-year survival, with area under the curve (AUC) values of 0.722 and 0.788, respectively. A Gal-3 cut-off value of 15.154 ng/mL was found to predict survival. Kaplan-Meier survival analysis revealed a significant difference in mean overall survival between patients with Gal-3 levels below and above the established cut-off (69.2 months versus 42.1 months, respectively; <i>p</i> = 0.036). Multivariate analysis confirmed that Gal-3 > 15.154 ng/mL remained an independent predictor of survival (HR 2.451, 95% CI 1.017-5.910, <i>p</i> = 0.046).</p><p><strong>Conclusions: </strong>This study suggests that Gal-3 holds independent prognostic value for survival in patients with cardiac AL amyloidosis. Gal-3 could potentially enhance the prognostic capabilities of the current soluble markers, thereby improving the management of cardiac AL amyloidosis. However, further validation in larger prospective studies is warranted.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonella Galeone, Fabiola Perrone, Gabriele Pesarini, Flavio Luciano Ribichini, Renato Di Gaetano, Giovanni Battista Luciani, Francesco Onorati
Background: The transfemoral approach represents the optimal access for TAVI due to its low invasiveness; however, up to 10-15% of TAVI candidates are considered unsuitable for femoral access because of significant peripheral vascular disease and need alternative access.
Methods: This is a single-center retrospective observational study including all consecutive adult patients undergoing transcatheter procedures through a TA approach from March 2015 to April 2024.
Results: 213 patients underwent transcatheter aortic or mitral valve implantation through a TA approach and were enrolled in this study. The mean age of the patients was 79.5 ± 5.7 years, and 54% of the patients were males. The mean Euroscore II was 7.9 ± 6.4%. One-third of the patients had previous cardiac surgery. The overall mean survival time was 5.3 ± 0.3 years. Nine (4%) patients developed infective endocarditis (IE) during the follow-up.
Conclusions: The transapical approach for transcatheter procedures is a safe and effective procedure for patients unsuitable for TF access with low periprocedural mortality and a low rate of post-procedural complications when performed by experienced surgeons and cardiologists.
背景:经股动脉入路由于创伤小,是TAVI的最佳入路;然而,高达10%-15%的TAVI候选者由于严重的外周血管疾病而被认为不适合股动脉入路,需要其他入路:这是一项单中心回顾性观察研究,包括2015年3月至2024年4月期间通过TA入路接受经导管手术的所有连续成年患者。结果:213名患者通过TA入路接受了经导管主动脉瓣或二尖瓣植入术,并被纳入本研究。患者的平均年龄为(79.5±5.7)岁,54%为男性。平均欧洲评分 II 为 7.9 ± 6.4%。三分之一的患者曾接受过心脏手术。总平均存活时间为 5.3 ± 0.3 年。9名(4%)患者在随访期间患上了感染性心内膜炎(IE):结论:对于不适合接受经导管介入手术的患者来说,经心尖介入经导管手术是一种安全有效的手术,如果由经验丰富的外科医生和心脏病专家实施,其围手术期死亡率低,术后并发症发生率低。
{"title":"Ten-Year Experience with a Transapical Approach for Transcatheter Aortic and Mitral Valve Implantation.","authors":"Antonella Galeone, Fabiola Perrone, Gabriele Pesarini, Flavio Luciano Ribichini, Renato Di Gaetano, Giovanni Battista Luciani, Francesco Onorati","doi":"10.3390/jcdd11070201","DOIUrl":"10.3390/jcdd11070201","url":null,"abstract":"<p><strong>Background: </strong>The transfemoral approach represents the optimal access for TAVI due to its low invasiveness; however, up to 10-15% of TAVI candidates are considered unsuitable for femoral access because of significant peripheral vascular disease and need alternative access.</p><p><strong>Methods: </strong>This is a single-center retrospective observational study including all consecutive adult patients undergoing transcatheter procedures through a TA approach from March 2015 to April 2024.</p><p><strong>Results: </strong>213 patients underwent transcatheter aortic or mitral valve implantation through a TA approach and were enrolled in this study. The mean age of the patients was 79.5 ± 5.7 years, and 54% of the patients were males. The mean Euroscore II was 7.9 ± 6.4%. One-third of the patients had previous cardiac surgery. The overall mean survival time was 5.3 ± 0.3 years. Nine (4%) patients developed infective endocarditis (IE) during the follow-up.</p><p><strong>Conclusions: </strong>The transapical approach for transcatheter procedures is a safe and effective procedure for patients unsuitable for TF access with low periprocedural mortality and a low rate of post-procedural complications when performed by experienced surgeons and cardiologists.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paula Vela Martín, Carlos Arellano Serrano, Álvaro Lorente Ros, Juan Francisco Oteo, Arturo Garcia-Touchard
Optical Coherence Tomography (OCT) imaging is a valuable tool for complex coronary interventions. While complications are rare, the occurrence of ventricular arrhythmias during its use is one of the most feared. Unfortunately, the mechanism by which these arrhythmias arise remains unclear. We describe the case of a patient under continuous electrocardiographic (ECG) monitoring who experienced ventricular fibrillation during an OCT procedure. A detailed analysis of the ECG event sequence was performed, from the administration of the contrast medium to the onset of ventricular fibrillation. Utilizing the collected data, we examined potential precipitating factors based on the observed alterations in the electrocardiogram. A comprehensive understanding of the mechanisms underlying these arrhythmias is crucial for the development of preventive measures that avoid such incidents in the future.
光学相干断层扫描(OCT)成像是复杂冠状动脉介入治疗的重要工具。虽然并发症很少,但在使用过程中发生室性心律失常是最令人担忧的问题之一。遗憾的是,这些心律失常的发生机制仍不清楚。我们描述了一例在持续心电图(ECG)监测下的患者在进行 OCT 手术时发生室颤的病例。我们详细分析了从使用造影剂到心室颤动发生的心电图事件序列。利用收集到的数据,我们根据观察到的心电图变化研究了潜在的诱发因素。全面了解这些心律失常的发生机制对于制定预防措施以避免今后发生此类事件至关重要。
{"title":"Ventricular Fibrillation during Optical Coherence Tomography.","authors":"Paula Vela Martín, Carlos Arellano Serrano, Álvaro Lorente Ros, Juan Francisco Oteo, Arturo Garcia-Touchard","doi":"10.3390/jcdd11070200","DOIUrl":"10.3390/jcdd11070200","url":null,"abstract":"<p><p>Optical Coherence Tomography (OCT) imaging is a valuable tool for complex coronary interventions. While complications are rare, the occurrence of ventricular arrhythmias during its use is one of the most feared. Unfortunately, the mechanism by which these arrhythmias arise remains unclear. We describe the case of a patient under continuous electrocardiographic (ECG) monitoring who experienced ventricular fibrillation during an OCT procedure. A detailed analysis of the ECG event sequence was performed, from the administration of the contrast medium to the onset of ventricular fibrillation. Utilizing the collected data, we examined potential precipitating factors based on the observed alterations in the electrocardiogram. A comprehensive understanding of the mechanisms underlying these arrhythmias is crucial for the development of preventive measures that avoid such incidents in the future.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There was missing information in the back matter of the original publication [...].
原始出版物的封底缺少信息[......]。
{"title":"Correction: Liu et al. Weight Change and Risk of Atherosclerosis Measured by Carotid Intima-Media Thickness (cIMT) from a Prospective Cohort-Analysis of the First-Wave Follow-Up Data of the Canadian Longitudinal Study on Aging (CLSA). <i>J. Cardiovasc. Dev. Dis.</i> 2023, <i>10</i>, 435.","authors":"Jian Liu, Newman Siu Kwan Sze, Miya Narushima, Deborah O'Leary","doi":"10.3390/jcdd11070196","DOIUrl":"10.3390/jcdd11070196","url":null,"abstract":"<p><p>There was missing information in the back matter of the original publication [...].</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Persistent Patent Ductus Arteriosus (PDA) is prevalent among extremely preterm infants, with its occurrence inversely related to gestational age. A persistent PDA correlates with increased mortality and morbidities such as intraventricular hemorrhage, pulmonary hemorrhage, chronic lung disease, bronchopulmonary dysplasia, and necrotizing enterocolitis as observed clinically. Conversely, numerous randomized controlled trials have failed to demonstrate significant benefits from PDA treatment. One contributing factor to these conflicting findings is that PDA affects each individual differently depending on the cardiovascular decompensation and its hemodynamic impact. PDA management should be based on the hemodynamic significance, rather than just the presence or size of PDA. This comprehensive narrative review paper describes echocardiographic parameters that allow a better understanding of the hemodynamic impact of PDA. A newer modality, like lung ultrasound, is also described here as an adjunct to assess the PDA impact on the lungs from pulmonary overcirculation.
{"title":"Narrative Review on Echocardiographic Evaluation of Patent Ductus Arteriosus in Preterm Infants.","authors":"Yogen Singh, Belinda Chan, Shahab Noori, Rangasamy Ramanathan","doi":"10.3390/jcdd11070199","DOIUrl":"10.3390/jcdd11070199","url":null,"abstract":"<p><p>Persistent Patent Ductus Arteriosus (PDA) is prevalent among extremely preterm infants, with its occurrence inversely related to gestational age. A persistent PDA correlates with increased mortality and morbidities such as intraventricular hemorrhage, pulmonary hemorrhage, chronic lung disease, bronchopulmonary dysplasia, and necrotizing enterocolitis as observed clinically. Conversely, numerous randomized controlled trials have failed to demonstrate significant benefits from PDA treatment. One contributing factor to these conflicting findings is that PDA affects each individual differently depending on the cardiovascular decompensation and its hemodynamic impact. PDA management should be based on the hemodynamic significance, rather than just the presence or size of PDA. This comprehensive narrative review paper describes echocardiographic parameters that allow a better understanding of the hemodynamic impact of PDA. A newer modality, like lung ultrasound, is also described here as an adjunct to assess the PDA impact on the lungs from pulmonary overcirculation.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction: Raiola et al. Imaging Approaches and the Quantitative Analysis of Heart Development. <i>J. Cardiovasc. Dev. Dis.</i> 2023, <i>10</i>, 145.","authors":"Morena Raiola, Miquel Sendra, Miguel Torres","doi":"10.3390/jcdd11070197","DOIUrl":"10.3390/jcdd11070197","url":null,"abstract":"<p><p>In the published publication [...].</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Several studies have shown that sodium-dependent glucose transporter 2 inhibitors can be used in the treatment of heart failure. This article summarized systematic reviews of sodium-dependent glucose transporter 2 inhibitors in the treatment of heart failure in order to evaluate efficacy and safety. Methods: We systematically searched eight electronic databases from inception to July 2023. We used Assessment of Multiple Systematic Reviews 2 to evaluate the methodological quality, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 to assess report quality, Risk of Bias in Systematic Review to assess the risk of bias, and Grading of Recommendations Assessment, Development, and Evaluation to rate the quality of evidence. Outcome: A total of 36 systematic reviews were included. Our results were classified as clear evidence of benefit: hospitalization for heart failure; possible benefit: cardiovascular death (mortality) and renal outcome composite; clear evidence of no effect or equivalence: atrial arrhythmias, ventricular arrhythmia, atrial fibrillation, and hypotension; possible harm: genital infection; insufficient evidence to draw a conclusion: atrial flutter, major adverse cardiovascular events, urinary tract infection, acute kidney injury, hypoglycemia, and bone fracture. Conclusions: Sodium-dependent glucose transporter 2 inhibitors are beneficial for the treatment of heart failure, especially in terms of heart failure hospitalization.
背景:多项研究表明,钠依赖性葡萄糖转运体 2 抑制剂可用于治疗心力衰竭。本文总结了钠依赖性葡萄糖转运体 2 抑制剂治疗心力衰竭的系统综述,以评估其疗效和安全性。方法:我们系统检索了从开始到 2023 年 7 月的 8 个电子数据库。我们采用《多重系统综述评估 2》(Assessment of Multiple Systematic Reviews 2)来评估方法学质量,采用《2020 年系统综述和荟萃分析首选报告项目》(Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020)来评估报告质量,采用《系统综述偏倚风险》(Risk of Bias in Systematic Review)来评估偏倚风险,采用《建议评估、制定和评价分级》(Grading of Recommendations Assessment, Development, and Evaluation)来评定证据质量。结果:共纳入 36 篇系统综述。我们的研究结果被归类为有明确证据证明获益:心力衰竭住院治疗;可能获益:心血管死亡(死亡率)和肾脏综合结果;有明确证据证明无影响或等效:房性心律失常、室性心律失常、心房颤动和低血压;可能有害:生殖器感染;证据不足以得出结论:心房扑动、主要不良心血管事件、尿路感染、急性肾损伤、低血糖和骨折。结论钠依赖性葡萄糖转运体 2 抑制剂有利于治疗心力衰竭,尤其是减少心力衰竭的住院时间。
{"title":"Sodium-Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews.","authors":"Yixuan Fang, Lihong Chen, Shiyi Sun, Xingwu Ran","doi":"10.3390/jcdd11070198","DOIUrl":"10.3390/jcdd11070198","url":null,"abstract":"<p><p><b>Background:</b> Several studies have shown that sodium-dependent glucose transporter 2 inhibitors can be used in the treatment of heart failure. This article summarized systematic reviews of sodium-dependent glucose transporter 2 inhibitors in the treatment of heart failure in order to evaluate efficacy and safety. <b>Methods:</b> We systematically searched eight electronic databases from inception to July 2023. We used Assessment of Multiple Systematic Reviews 2 to evaluate the methodological quality, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 to assess report quality, Risk of Bias in Systematic Review to assess the risk of bias, and Grading of Recommendations Assessment, Development, and Evaluation to rate the quality of evidence. <b>Outcome:</b> A total of 36 systematic reviews were included. Our results were classified as clear evidence of benefit: hospitalization for heart failure; possible benefit: cardiovascular death (mortality) and renal outcome composite; clear evidence of no effect or equivalence: atrial arrhythmias, ventricular arrhythmia, atrial fibrillation, and hypotension; possible harm: genital infection; insufficient evidence to draw a conclusion: atrial flutter, major adverse cardiovascular events, urinary tract infection, acute kidney injury, hypoglycemia, and bone fracture. <b>Conclusions:</b> Sodium-dependent glucose transporter 2 inhibitors are beneficial for the treatment of heart failure, especially in terms of heart failure hospitalization.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11276734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}